thalidomide / Generic mfg. - LARVOL DELTA

CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS OF ACTINIC PRURIGO OVER A 15-YEAR SPAN IN A MEXICAN TERTIARY CARE HOSPITAL CENTER (AAD 2026) - "Topical corticosteroids and calcineurin inhibitors are recommended for mild cases, while thalidomide remains the most effective therapy for refractory cases. Additional systemic therapies include oral corticosteroids, immunosuppressants, phototherapy, biologics, antimalarials and Polypodium leucotomos extract...Mucosal involvement (lip or ocular) occurs in about one-third. Diagnosis is often delayed and biopsy confirmation is rarely required."

Clinical • Hematological Disorders • Infectious Disease • Ocular Infections • HLA-DRB1

Reported Patterns and Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Associated with Novel Antineoplastic Therapies: A Retrospective Pharmacovigilance Analysis (AAD 2026) - "Introduction: Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is a severe, life-threatening drug reaction traditionally linked to anticonvulsants and allopurinol...Positive signals for DRESS were observed with several drugs, including imatinib, vemurafenib, thalidomide, brentuximab vedotin, and temozolomide. In contrast, drugs like nivolumab, rituximab, and denosumab showed negative signals... Our findings describe an emerging association of DRESS syndrome with novel antineoplastic therapies. The varied risk of DRESS across agents within the same class suggests that it is not necessarily a class-wide hypersensitivity. This highlights the need for increased clinician awareness to aid early recognition and prompt drug withdrawal to improve patient outcomes."

Adverse events • Retrospective data • Eosinophilia • Immunology

Comparison of Maintenance Strategies Following Quadruplet Induction in Newly Diagnosed Myeloma (HOPA 2026) - "In the CASSIOPEIA study, patients received daratumumab maintenance or observation after daratumumab-bortezomib-thalidomide-dexamethasone induction, whereas in PERSEUS, patients received lenalidomide maintenance daratumumab-bortezomib-lenalidomide-dexamethasone induction. In progress"

Clinical • Hematological Malignancies • Multiple Myeloma

Nanoparticle-mediated restoration of pomalidomide sensitivity in multiple myeloma (AACR 2026) - "FDA approved IMiDs (thalidomide, lenalidomide, and pomalidomide) have remained among the primary treatments for MM and have helped extend the lifespan of patients up to several years after diagnosis. These peptides have been synthesized and are being tested; they will be conjugated with the nanoparticle-coated cereblon mRNA for targeted delivery to the malignant plasma cells. Our results show that delivery of cereblon mRNA to pomalidomide-resistant cells using lipid nanoparticles led to substantial restoration of pomalidomide sensitivity."

IO biomarker • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • CD38 • CRBN

The B-hCRBN mice model facilitates PROTACs studies based on CRBN ligands (AACR 2026) - "In the treatment of multiple myeloma (MM), immunomodulatory drugs targeting CRBN (such as thalidomide and lenalidomide) show significant efficacy. In summary, the development of the B-hCRBN mouse model has been successful, as it successfully expresses the human CRBN protein and can be used functionally. Tumor cell lines inoculated in B-hCRBN mice can be used to study the in vivo efficacy and safety evaluation of CRBN small molecule drugs, molecular glue drugs based on CRBN, or PROTAC drugs based on CRBN."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • CD4 • CRBN • CUL4A • DDB1 • IL17RB

B-lymphoblastic leukemia (B-ALL) following thalidomide analog therapy: A multi-institutional comparison with therapy-related and de novo B-ALL. (USCAP 2026) - "Background: B-lymphoblastic leukemia (B-ALL) arising after multiple myeloma (MM) therapy is increasingly recognized, particularly in patients exposed to thalidomide analogs (lenalidomide [LEN], pomalidomide [POM]). B-ALL post-MM therapy may represent a distinct entity, characterized by fewer BCR::ABL1 fusions, frequent TP53 mutations, and spontaneous regression after LEN withdrawal in rare cases. Despite similar survival to other cohorts, the unique clinical and genetic profile supports recognizing this subset separately from conventional TR-B-ALL. These findings highlight the need for close surveillance of patients on thalidomide analog therapy and promote further studies to explore the underlying mechanisms of leukemogenesis."

Clinical • Hematological Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • ABL1 • ETV6 • IKZF1 • KMT2A • RUNX1 • TP53

B-lymphoblastic leukemia (B-ALL) following thalidomide analog therapy: A multi-institutional comparison with therapy-related and de novo B-ALL. (USCAP 2026) - "Background: B-lymphoblastic leukemia (B-ALL) arising after multiple myeloma (MM) therapy is increasingly recognized, particularly in patients exposed to thalidomide analogs (lenalidomide [LEN], pomalidomide [POM]). B-ALL post-MM therapy may represent a distinct entity, characterized by fewer BCR::ABL1 fusions, frequent TP53 mutations, and spontaneous regression after LEN withdrawal in rare cases. Despite similar survival to other cohorts, the unique clinical and genetic profile supports recognizing this subset separately from conventional TR-B-ALL. These findings highlight the need for close surveillance of patients on thalidomide analog therapy and promote further studies to explore the underlying mechanisms of leukemogenesis."

Clinical • Hematological Disorders • Hematological Malignancies • Leukemia • Multiple Myeloma • ABL1 • ETV6 • IKZF1 • KMT2A • RUNX1 • TP53

Updates to the WHO Classification of Pancreatobiliary Tumors: Key Changes for Clinical Practice (USCAP 2026) - "Carboplatin and thalidomide chemotherapy was performed Two years later, abdominal recurrence associated with a new increase of AFP serum level was observed and he continued chemotherapy. Metastases have been reported in 41% of cases, being loco-regional in 26% of the cases and distant in 22%. Evening Specialty Presentation (PDF): Click to View"

Clinical • Biliary Cancer • Cardiovascular • Cushing’s Disease • Endocrine Disorders • Hepatology • Hypertension • Musculoskeletal Pain • Obesity • Oncology • Pancreatic Cancer • Solid Tumor • AFP • CD99 • CHGA • CK19 • KRT19 • MME • PGR • SYP

Efficacy and Safety of Thalidomide Combined With Glutamine in the Treatment of Radiation Intestinal Injury. (clinicaltrials.gov) - P2 | N=150 | Recruiting | Sponsor: Yongquan Shi | Not yet recruiting ➔ Recruiting | Trial completion date: Oct 2026 ➔ Nov 2028 | Trial primary completion date: Oct 2025 ➔ Oct 2028

Enrollment open • Trial completion date • Trial primary completion date • Gastrointestinal Disorder

Five children with haploinsufficiency of A20 caused by heterozygous mutations in the TNFAIP3 gene. (PubMed, Front Immunol) - "Each child was treated with the oral drug thalidomide, 4 children (80%) received glucocorticoids to reduce inflammation, and had different biological agents according to individual differences...It can present with a variety of clinical manifestations, including Behcet disease, inflammatory bowel disease, lupus-like syndrome and periodic fever syndrome. Whole-exome sequencing should be actively considered for children who present with early-onset symptoms or features suggestive of autoimmune diseases."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Pediatrics • CRP • TNFAIP3

THE EFFICACY AND SAFETY OF PD-1 MONOCLONAL ANTIBODY IN THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME:SYSTEMATIC REVIEW (EBMT 2026) - "Data regarding the efficacy and safety of PD-1 monoclonal antibodies used (such as sintilimab, nivolumab, camrelizumab, and tislelizumab) in both pediatric and adult patients with HLH were included...In pediatric patients (aged 3–7 years) with CAEBV and r/r EBV-HLH, sintilimab (3mg/kg, once every 3-4 weeks, monotherapy or combined with L-DEP regimen (pegaspargase, liposomal doxorubicin, etoposide, and high-dose methylprednisolone)) induced partial or complete clinical remission and significantly reduced plasma EBV-DNA levels (>50%), successfully serving as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in some cases...Furthermore, novel combinations with ruxolitinib, venetoclax, or thalidomide achieved rapid clinical remission in EBV-HLH... PD-1 monoclonal antibodies demonstrate significant therapeutic potential as salvage therapy for r/r EBV-HLH, effectively reducing viral loads and inducing remission. However, immune checkpoint inhibition acts..."

Clinical • Review • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Natural Killer/T-cell Lymphoma • Rare Diseases • T Cell Non-Hodgkin Lymphoma

PROGNOSTIC DIFFERENCES AMONG PATIENTS WITH MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN, TAIWAN, AND MALAYSIA: IMPACT OF PRE-TRANSPLANT PI/IMID-BASED THERAPIES (EBMT 2026) - "VRD induction was associated with superior PFS and OS compared with VTD/VTCD, contributing to observed international outcome differences. Maintenance using lenalidomide or thalidomide was not significant. Access to lenalidomide—both for induction and maintenance—varied markedly across countries and likely influenced prognosis."

Clinical • Pre-transplantation • Bone Marrow Transplantation • Hematological Malignancies • Multiple Myeloma • Transplantation

COMPARISON OF DARA-VTD AND TRIPLE THERAPY AS INDUCTION REGIMENS PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (EBMT 2026) - "Background: Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) has emerged as an effective first-line induction regimen for patients with newly diagnosed plasma cell myeloma (PCM). Induction with four cycles of Dara-VTD results in significantly deeper responses, including higher MRD-negative rates, prior to AHCT in newly diagnosed PCM. However, these benefits are accompanied by an increased incidence of severe infectious complications during both induction and transplantation, as well as delayed hematopoietic recovery. The relationship between delayed neutrophil recovery, daratumumab exposure, and infection risk warrants further investigation."

Hematological Malignancies • Infectious Disease • Multiple Myeloma • Transplantation

TYPE OF INDUCTION CHEMOTHERAPY INFLUENCES STEM CELL MOBILIZATION CAPACITY IN MULTIPLE MYELOMA PATIENTS – COMPARISON OF VCD VS DARA-VTD IN A LARGE MULTICENTER COHORT (EBMT 2026) - "Patients had to receive first line induction treatment of MM containing of either bortezomib, cyclophosphamide and dexamethasone (VCD) or daratumumab, bortezomib, thalidomide and dexamethasone (D-VTD)...Evaluated parameters included amongst others: patient characteristics such as age, sex, cytogenetic risk profile, additional use of plerixafor, day of first apheresis, pB CD34+ cells/µL on first day of apheresis, total number of aphereses, cumulative yield of CD34+ cells... Our real-world data shows significant differences in PBSC mobilization outcomes between VCD and D-VTD induction therapies in transplant-eligible MM patients. Whether this effect can be attributed to novel drug classes included or antibody pharmacokinetics is currently unclear. Optimal settings for PBSC mobilization in these have to be determined in the future."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • CD34

CHRONIC GRAFT-VERSUS-HOST DISEASE: REAL-WORLD OUTCOMES AND EFFICACY OF RUXOLITINIB COMPARED WITH CONVENTIONAL TREATMENTS (EBMT 2026) - " Among 229 cGVHD patients requiring second-line treatment, 125 (55%) received ruxolitinib and 104 (45%) received conventional agents, primarily thalidomide (54%) and sirolimus (14%). Our results showed that ruxolitinib was superior to conventional second-line agents for steroid-refractory cGVHD in ORR, failure-free survival, and successful immunosuppression tapering. These findings support ruxolitinib as the preferred second-line treatment for most patients with cGVHD. However, pulmonary GVHD remains an unmet clinical need, representing an important area for future therapeutic development and investigation."

Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Infectious Disease

THE EFFICACY AND SAFETY OF PD-1 MONOCLONAL ANTIBODY IN THE TREATMENT OF HEMOPHAGOCYTIC SYNDROME:SYSTEMATIC REVIEW (EBMT 2026) - "Data regarding the efficacy and safety of PD-1 monoclonal antibodies used (such as sintilimab, nivolumab, camrelizumab, and tislelizumab) in both pediatric and adult patients with HLH were included...In pediatric patients (aged 3–7 years) with CAEBV and r/r EBV-HLH, sintilimab (3mg/kg, once every 3-4 weeks, monotherapy or combined with L-DEP regimen (pegaspargase, liposomal doxorubicin, etoposide, and high-dose methylprednisolone)) induced partial or complete clinical remission and significantly reduced plasma EBV-DNA levels (>50%), successfully serving as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in some cases...Furthermore, novel combinations with ruxolitinib, venetoclax, or thalidomide achieved rapid clinical remission in EBV-HLH... PD-1 monoclonal antibodies demonstrate significant therapeutic potential as salvage therapy for r/r EBV-HLH, effectively reducing viral loads and inducing remission. However, immune checkpoint inhibition acts..."

Clinical • Review • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Graft versus Host Disease • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Natural Killer/T-cell Lymphoma • Rare Diseases • T Cell Non-Hodgkin Lymphoma

OUTCOMES OF SECOND AUTOLOGOUS STEM CELL TRANSPLANTATION AS RESCUE THERAPY IN RELAPSED MULTIPLE MYELOMA PATIENT, WITHOUT CRYOPRESERVED CD34. CASE REPORT FROM TRANSPLANT CENTER IN VENEZUELA (EBMT 2026) - "Complete Response was achieved by day 120 post-ASCT, and she received maintenance therapy with thalidomide for 2 years.8 years after the first ASCT, the patient suffered a relapsed and received treatment with Cyclophosphamide, bortezomib, and dexamethasone for 8 cycles, obtaining a VGPR, she underwent a 2ASCT; using fresh collectedGCSF-mobilized PB stem cells as source, a total of 2x106cells/kg CD34 cells was obtained, the conditioning regimen of choice was Melphalan 200mg/m2 (Mel200)...Currently, she has been on Lenalidomide as maintenance therapy for the last 2 years... A 2ASCT in an RMM patient had low toxicity and was associated with a good OS and EFS in our patient. The use of Melphalan as a conditioning regimen in previous ASTC had no impact on a second mobilization and collection of GCSF-mobilized PB stem cells. A VGPR before proceeding to a 2ASCT is key for a better outcome; however, we need more data to statistically prove our results."

Case report • Clinical • Bone Marrow Transplantation • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Transplantation • CD34

IS THERE STILL A CURATIVE ROLE FOR ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA? LONG-TERM OUTCOMES IN YOUNG PATIENTS UNDERGOING HLA-IDENTICAL ALLOGENEIC HAEMATOPIETIC STEM CELL TRANSPLANT (EBMT 2026) - "Herein we report the long-term overall survival (OS), relapse-free survival (RFS), graft-versus-host disease–free relapse-free survival (GRFS), and cumulative incidence of relapse and NRM in a cohort of young MM patients exposed to bortezomib- and/or thalidomide-based therapies...Despite the absence of post-transplant cyclophosphamide, GVHD was clinically manageable and did not preclude long-term survival, supporting a clinically relevant graft-versus-myeloma effect in selected young patients... Despite advances in non-transplant therapies, allo-HSCT retains a potential curative role in carefully selected young MM patients. Early transplantation and the availability of an HLA-identical sibling donor appear to be critical determinants of long-term survival and disease control. These findings support reconsidering allo-HSCT as a curative strategy rather than a purely palliative option in the modern treatment landscape of MM."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Multiple Myeloma • Transplantation

COMPARISON OF DARA-VTD AND TRIPLE THERAPY AS INDUCTION REGIMENS PRIOR TO AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (EBMT 2026) - "Background: Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) has emerged as an effective first-line induction regimen for patients with newly diagnosed plasma cell myeloma (PCM). Induction with four cycles of Dara-VTD results in significantly deeper responses, including higher MRD-negative rates, prior to AHCT in newly diagnosed PCM. However, these benefits are accompanied by an increased incidence of severe infectious complications during both induction and transplantation, as well as delayed hematopoietic recovery. The relationship between delayed neutrophil recovery, daratumumab exposure, and infection risk warrants further investigation."

Hematological Malignancies • Infectious Disease • Multiple Myeloma • Transplantation

PROGNOSTIC DIFFERENCES AMONG PATIENTS WITH MULTIPLE MYELOMA UNDERGOING UPFRONT AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JAPAN, TAIWAN, AND MALAYSIA: IMPACT OF PRE-TRANSPLANT PI/IMID-BASED THERAPIES (EBMT 2026) - "VRD induction was associated with superior PFS and OS compared with VTD/VTCD, contributing to observed international outcome differences. Maintenance using lenalidomide or thalidomide was not significant. Access to lenalidomide—both for induction and maintenance—varied markedly across countries and likely influenced prognosis."

Clinical • Pre-transplantation • Bone Marrow Transplantation • Hematological Malignancies • Multiple Myeloma • Transplantation

TAKOTSUBO CARDIOMYOPATHY MIMICKING ACUTE CORONARY SYNDROME DURING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (EBMT 2026) - "Due to elevated liver enzymes, thalidomide was discontinued and therapy was adjusted to CYBORDEX (cyclophosphamide, bortezomib, dexamethasone). This case highlights Takotsubo cardiomyopathy as an important and under-recognized differential diagnosis of acute coronary syndrome during autologous HSCT. Transplant-related physical stress and acute procedural complications may act as triggers. Awareness of this condition among transplant teams is essential to ensure appropriate diagnosis, optimize management, and prevent unnecessary invasive interventions."

Acute Coronary Syndrome • Bone Marrow Transplantation • Cardiomyopathy • Cardiovascular • CNS Disorders • Coronary Artery Disease • Epilepsy • Hematological Disorders • Hypotension • Infectious Disease • Myocardial Infarction • Plasmacytoma • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Transplantation • CD34

TYPE OF INDUCTION CHEMOTHERAPY INFLUENCES STEM CELL MOBILIZATION CAPACITY IN MULTIPLE MYELOMA PATIENTS – COMPARISON OF VCD VS DARA-VTD IN A LARGE MULTICENTER COHORT (EBMT 2026) - "Patients had to receive first line induction treatment of MM containing of either bortezomib, cyclophosphamide and dexamethasone (VCD) or daratumumab, bortezomib, thalidomide and dexamethasone (D-VTD)...Evaluated parameters included amongst others: patient characteristics such as age, sex, cytogenetic risk profile, additional use of plerixafor, day of first apheresis, pB CD34+ cells/µL on first day of apheresis, total number of aphereses, cumulative yield of CD34+ cells... Our real-world data shows significant differences in PBSC mobilization outcomes between VCD and D-VTD induction therapies in transplant-eligible MM patients. Whether this effect can be attributed to novel drug classes included or antibody pharmacokinetics is currently unclear. Optimal settings for PBSC mobilization in these have to be determined in the future."

Clinical • IO biomarker • Hematological Malignancies • Multiple Myeloma • CD34

THALIDOMIDE TREATMENT FOR HEMODIALYSIS COMPLICATED WITH INTESTINAL VASCULAR DYSPLASIA (ISN-WCN 2026) - "At the 3-month post-discontinuation assessment: Hemoglobin remained stable at 85 g/L,no recurrent gastrointestinal bleeding,persistent absence of fecal occult blood.Conclusion Colonoscopy proves instrumental in diagnosing refractory gastrointestinal bleeding during maintenance hemodialysis. Thalidomide demonstrates clinical efficacy for hemodialysis-associated intestinal vascular dysplasia-related hemorrhage, likely mediated through inhibition of vascular endothelial growth factor production.Declaration of Generative AI and AI-assisted technologies in the writing process."

Cardiovascular • Chronic Kidney Disease • Gastroenterology • Glomerulonephritis • Hematological Disorders • IgA Nephropathy • Metabolic Disorders • Nephrology • Renal Disease

CEREBLON HOMEOSTASIS IS PERTURBED BY TRAUMATIC BRAIN INJURY AND CRITICAL FOR MITOCHONDRIAL DYNAMICS (ADPD 2026) - "We exposed these cells to thalidomide treatment to further modulate their activity of cereblon, as well as performed in vitro TBI to assess the response to injury... Our data indicate that upsetting the homeostatic balance of cereblon in either direction has deleterious effects on brain health. This identifies unique considerations of the challenges of altering cereblon levels to achieve therapeutic benefit."

Alzheimer's Disease • CNS Disorders • Dementia • Developmental Disorders • Mental Retardation • Targeted Protein Degradation • Vascular Neurology • CRBN

Thalidomide as adjunctive therapy in corticosteroid-refractory cerebral tuberculomas: experience from Donostia University Hospital (ESCMID Global 2026) - No abstract available

Clinical • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis